Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial February 16, 2023May 23, 2023
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder August 31, 2023August 31, 2023
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe August 25, 2022May 23, 2023